From pre-orders to market entry, Rokid’s Taiwan campaign reflects how AI hardware is being introduced to consumers today.
Updated
January 8, 2026 6:30 PM
Rokid Glasses, a pair of AR glasses from Rokid. PHOTO: ROKID
Rokid has reached a significant crowdfunding milestone in Taiwan. Its Rokid Glasses campaign surpassed NT$62 million in pre-order funding on zeczec, Taiwan’s creative-oriented crowdfunding platform. The campaign ranked No. 1 across all categories on the platform in 2025 and entered the Top 10 funded campaigns in zeczec’s history, setting new records for AI and XR-related projects.
The campaign launched on October 28 and became one of the platform’s most prominent technology initiatives of the year. According to the company, the outcome followed growing visibility for Rokid Glasses after product showcases in New York, Berlin, Singapore and Paris, positioning the Taiwan campaign within a broader international rollout.
The crowdfunding achievement coincided with Rokid’s official market entry in Taiwan. On December 10, the company debuted Rokid Glasses locally, introducing the product to media, partners and early users in the region. The Taiwan launch mirrored earlier international events and connected the online crowdfunding campaign with a physical market presence.
Rokid Glasses combine augmented reality displays with built-in AI functions, including real-time multilingual translation, live transcription, navigation, object recognition and voice assistance. These capabilities were central to how the product was presented during both the crowdfunding campaign and the Taiwan launch, without framing the project as a traditional consumer electronics release.
The Taiwan campaign builds on Rokid’s prior crowdfunding history. The company previously raised more than US$4 million on Kickstarter, where Rokid Glasses became the highest-funded XR wearable project on the platform. The zeczec campaign extends that track record into one of Asia’s most established consumer electronics markets.
“Taiwan has one of the world's most mature and discerning consumer electronics markets”, said Said Justo Chang, Head of Global Channels at Rokid. “Reaching the top of Taiwan's crowdfunding platform is a great commercial achievement. We are excited to finally introduce Rokid Glasses to Taiwan”.
More broadly, the campaign highlights how crowdfunding platforms continue to function as launch and distribution channels for emerging AI and XR hardware. In Rokid’s case, product rollout, market entry and public participation converged within a single campaign, marking a notable moment for AI-enabled wearables in Taiwan’s technology landscape.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.